These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29968252)

  • 1. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.
    Komor MA; de Wit M; van den Berg J; Martens de Kemp SR; Delis-van Diemen PM; Bolijn AS; Tijssen M; Schelfhorst T; Piersma SR; Chiasserini D; Sanders J; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; Carvalho B; Meijer GA; Jimenez CR; Fijneman RJA;
    Int J Cancer; 2020 Apr; 146(7):1979-1992. PubMed ID: 31411736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus molecular subtype transition during progression of colorectal cancer.
    van de Weerd S; Torang A; Zwager LW; Koelink PJ; Koster J; Bastiaansen BA; Lammers V; Longobardi C; Roodhart JM; van Krieken JH; Farina Sarasqueta A; Dekker E; Medema JP
    J Pathol; 2023 Nov; 261(3):298-308. PubMed ID: 37681286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains.
    Berg KCG; Sveen A; Høland M; Alagaratnam S; Berg M; Danielsen SA; Nesbakken A; Søreide K; Lothe RA
    Oncogene; 2019 Aug; 38(33):6109-6122. PubMed ID: 31308487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles in genome instability-based classes of colorectal cancer.
    Barresi V; Cinnirella G; Valenti G; Spampinato G; Musso N; Castorina S; Condorelli DF
    BMC Cancer; 2018 Dec; 18(1):1265. PubMed ID: 30563495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
    Komor MA; Bosch LJ; Coupé VM; Rausch C; Pham TV; Piersma SR; Mongera S; Mulder CJ; Dekker E; Kuipers EJ; van de Wiel MA; Carvalho B; Fijneman RJ; Jimenez CR; Meijer GA; de Wit M
    J Pathol; 2020 Mar; 250(3):288-298. PubMed ID: 31784980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
    Meng H; Li W; Boardman LA; Wang L
    BMC Cancer; 2018 Apr; 18(1):433. PubMed ID: 29661177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 16. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back to the Colorectal Cancer Consensus Molecular Subtype Future.
    Menter DG; Davis JS; Broom BM; Overman MJ; Morris J; Kopetz S
    Curr Gastroenterol Rep; 2019 Jan; 21(2):5. PubMed ID: 30701321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The consensus molecular subtypes of colorectal cancer.
    Guinney J; Dienstmann R; Wang X; de Reyniès A; Schlicker A; Soneson C; Marisa L; Roepman P; Nyamundanda G; Angelino P; Bot BM; Morris JS; Simon IM; Gerster S; Fessler E; De Sousa E Melo F; Missiaglia E; Ramay H; Barras D; Homicsko K; Maru D; Manyam GC; Broom B; Boige V; Perez-Villamil B; Laderas T; Salazar R; Gray JW; Hanahan D; Tabernero J; Bernards R; Friend SH; Laurent-Puig P; Medema JP; Sadanandam A; Wessels L; Delorenzi M; Kopetz S; Vermeulen L; Tejpar S
    Nat Med; 2015 Nov; 21(11):1350-6. PubMed ID: 26457759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.